Our drug portfolio focuses on the treatment of three cancers, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Our pancreatic cancer drug was developed at University of Texas at Austin. The new drug, “DHA-dFdC”, is a new compound that holds promising indications of becoming the next generation of chemotherapy treatment for advanced pancreatic cancer. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs and is well tolerated in preclinical toxicity tests. Preclinical studies have also indicated that the drug: Inhibits pancreatic cancer cell growth (up to 100,000-fold more potent that gemcitabine, a current standard therapy), Has documented efficacy against pancreatic tumors in a clinically relevant transgenic mouse model, Overcomes tumor cell resistance to current chemotherapeutic drugs, Is well tolerated in preclinical toxicity test, Has demonstrated activities against other cancers (e.g. leukemia, lung, melanoma)
Our AML drug, developed at Wake Forest Univeristy, is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs.
Combined, Spherix’s platform offers a robust drug pipeline focused on the development and commercialization of drugs to treat unmet medical needs in oncology.